Patent Interference Appeals Against Biopharmaceutical Company Dropped
7 Sep 2006
Two appeals in response to a set of patent interference rulings in favor of Geron Corporation have been dismissed. The patents concerned a technology applied in the technique of nuclear transfer, known familiarly as cloning.
In 1999, Geron, a biopharmaceutical corporation, obtained the intellectual property rights to the technology in question from the U.K.-based Roslin Institute. Following that acquisition, it filed what are known as "patent interference" claims against the University of Massachusetts (UMASS), for the University's holding of an apparently similar patent. The claim also extended to Advanced Cell Technology (ACT), which was a licensee of the University's technology. In response, UMASS and ACT appealed to the U.S. District Court for the District of Columbia.
However, UMASS and ACT have since dropped their appeals claims. Their decision to do so is a result of an agreement between them and a "joint venture" company by the name of stART Licensing, Inc.
Source: ag-IP-news. geron announces dismissal of patent interference appeals. AGIPNEWS3500. September 7, 2006.
Go to website
|
|
Related Categories
|
